Literature DB >> 6722741

Rate of growth of intraabdominal metastases from colorectal cancer.

I J Havelaar, P H Sugarbaker, M Vermess, D L Miller.   

Abstract

Monitoring the progression or regression of intraabdominal metastatic disease is required for knowledgeable management of chemotherapeutic regimens designed to treat metastases. Computerized tomography (CT) and CT with EOE-13, a liver contrast agent, allowed precise measurement of metastatic disease. The tumor doubling time of colorectal metastases in four patients was determined from serial CT scans of individual patients. Tumor doubling times of untreated patients varied from 50 to 95 days, and were in the same range for hepatic, lymph node, or intraperitoneal metastatic disease. These data may indicate that metastatic disease of colorectal cancer progresses at a faster rate in the peritoneal cavity than is reported for colorectal cancer metastatic to the lungs. The response to chemotherapy or progression of disease was also determined in treated patients. High resolution CT scanning with EOE-13 allowed calculation of tumor doubling times, and therefore more precise management of cancer patients with metastases.

Entities:  

Mesh:

Year:  1984        PMID: 6722741     DOI: 10.1002/1097-0142(19840701)54:1<163::aid-cncr2820540131>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Large bowel adenomas containing carcinoma--a diagnostic and therapeutic approach.

Authors:  F P Rossini; A Ferrari; S Coverlizza; M Spandre; M Risio; C Gemme; M Cavallero
Journal:  Int J Colorectal Dis       Date:  1988-03       Impact factor: 2.571

2.  Total parenteral nutrition prevents further nutritional deterioration in patients with cancer cachexia.

Authors:  F Bozzetti; M Ammatuna; S Migliavacca; M G Bonalumi; G Facchetti; A Pupa; G Terno
Journal:  Ann Surg       Date:  1987-02       Impact factor: 12.969

3.  Estimation of Solid Tumor Doubling Times from Progression-Free Survival Plots Using a Novel Statistical Approach.

Authors:  Katherine Kay; Keith Dolcy; Robert Bies; Dhaval K Shah
Journal:  AAPS J       Date:  2019-02-08       Impact factor: 4.009

4.  Utility of preoperative imaging in evaluating colorectal liver metastases declines over time.

Authors:  Simon Yang; Sermsak Hongjinda; Sherif S Hanna; Steven Gallinger; Alice C Wei; Alex Kiss; Calvin Law
Journal:  HPB (Oxford)       Date:  2010-09-02       Impact factor: 3.647

5.  Pre-hepatectomy prognostic staging to determine treatment strategy for colorectal cancer metastases to the liver.

Authors:  Kuniya Tanaka; Hiroshi Shimada; Yoshirou Fujii; Itaru Endo; Hitoshi Sekido; Shinji Togo; Hideyuki Ike
Journal:  Langenbecks Arch Surg       Date:  2004-07-03       Impact factor: 3.445

6.  Procedures of choice for resection of primary and recurrent liver metastases from colorectal cancer.

Authors:  Kuniya Tanaka; Hiroshi Shimada; Mitsuyoshi Ohta; Shinji Togo; Shuji Saitou; Shigeki Yamaguchi; Itaru Endo; Hitoshi Sekido
Journal:  World J Surg       Date:  2004-04-19       Impact factor: 3.352

7.  Metastatic tumor doubling time: most important prehepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis.

Authors:  Kuniya Tanaka; Hiroshi Shimada; Masaru Miura; Yoshiro Fujii; Shigeki Yamaguchi; Itaru Endo; Hitoshi Sekido; Shinji Togo; Hideyuki Ike
Journal:  World J Surg       Date:  2004-02-17       Impact factor: 3.352

8.  Patterns of failure following surgical resection of colorectal cancer liver metastases. Rationale for a multimodal approach.

Authors:  F Bozzetti; R Doci; P Bignami; A Morabito; L Gennari
Journal:  Ann Surg       Date:  1987-03       Impact factor: 12.969

9.  Liver transplantation for neuroendocrine tumors.

Authors:  Sander Florman; Ben Toure; Leona Kim; Gabriel Gondolesi; Sasan Roayaie; Nancy Krieger; Thomas Fishbein; Sukru Emre; Charles Miller; Myron Schwartz
Journal:  J Gastrointest Surg       Date:  2004-02       Impact factor: 3.452

Review 10.  Colorectal cancer: prevention and management of metastatic disease.

Authors:  Paul H Sugarbaker
Journal:  Biomed Res Int       Date:  2014-03-24       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.